Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients wi ...
An Investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of edoxaban versus warfarin (Vitamin K antagonist) in subjects with chronic thromboembolic pulmonaty hypertension taking warfarin (Vitamin K antagonist) at baseline - KABUKI An Investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-gr ...
Oral administeration of (1) or (2) (1) Edoxaban group - Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications)
(2)Warfarin group - Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications)
- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5) Oral administeration of (1) or (2) (1) Edoxabangroup - Edoxaban30 mg/60 mg tablet according to body w ...
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-gr ...
Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertens ...
Initiation of once-daily Edoxaban(60mg) during 6 months after 2 days discontinuation of warfarin
Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School ...